阿波利波蛋白E ε4状态与阿尔茨海默病风险之间的关联:元分析
Zijun Ren1, Zhenting Guan2, Qingliang Guan3
1Department of Neurology, Yanbian University hospital, City of Yanji, Jilin Province, China.
BMC neuroscience
|January 25, 2025
概括
阿波利波蛋白E ε4 (APOE ε4) 状态增加了阿尔茨海默病 (AD) 发生的风险. 这一元分析证实APOE ε4是阿尔茨海默病患者无病生存的重要预测因子.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 流行病学 流行病学
背景情况:
- 在阿尔茨海默病 (AD) 发病过程中,阿波利波蛋白E ε4 (APOE ε4) 的作用仍在争论中.
- 预测AD进展和事件风险对于患者管理至关重要.
研究的目的:
- 根据他们的APOE ε4状态,对患者的AD事件风险进行元分析.
- 为了澄清APOE ε4在AD患者的预后意义.
主要方法:
- 在Cochrane Library,EMBASE和PubMed数据库中进行系统的文献搜索.
- 包括1987年以后发表的22项英语研究.
- 分析聚合危险比率 (HRs) 以评估预后意义.
主要成果:
- 在AD患者中,APOE ε4状态被确定为无病生存 (DFS) 的重要风险因素 (HR = 2.033,95% CI = 1.589-2.602).
- 分析包括了571,800名患者,这表明了强有力的发现.
- 亚组分析强调ROC曲线是阿兹海默症患者的关键风险因素.
结论:
- 这些发现表明,在具有特定APOE ε4状态的个体中,AD事件的风险增加.
- 这一元分析提供了支持APOE ε4作为AD进展的风险因素的证据.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170